These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30842140)

  • 1. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors and Papillary Thyroid Cancer.
    Spartalis E; Kotrotsios K; Chrysikos D; Spartalis M; Paschou SA; Schizas D; Tsamakis K; Dimitroulis D; Troupis T; Nikiteas N
    Curr Pharm Des; 2021; 27(18):2199-2208. PubMed ID: 33308111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
    Damaskos C; Garmpis N; Valsami S; Spartalis E; Antoniou EA; Tomos P; Karamaroudis S; Zoumpou T; Pergialiotis V; Stergios K; Michaelides C; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
    Anticancer Res; 2016 Oct; 36(10):5019-5024. PubMed ID: 27798860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
    Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS
    BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Anticancer Activity of
    Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
    Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
    Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
    Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
    Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
    Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
    Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.
    Jang S; Yu XM; Odorico S; Clark M; Jaskula-Sztul R; Schienebeck CM; Kupcho KR; Harrison AD; Winston-McPherson GN; Tang W; Chen H
    Cancer Gene Ther; 2015 Aug; 22(8):410-6. PubMed ID: 26251030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
    Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
    J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
    Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.